SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced receiving pre-launch orders for their ABBIE Technology kits. This marks a significant milestone as the company transitions from R&D to commercialization of GLP ABBIE Technology Kits. The CRISPR/Cas9 kits market is projected to reach $17.4 billion by 2032.
SOHM's ABBIE technology offers faster and more efficient integration of genetic sequences into cell DNA compared to traditional methods, reducing time and costs. The company's data shows that ABBIE expressing mRNA with guide RNAs integrates donor DNA more efficiently than without guide RNAs.
Management is confident that these pre-launch orders will open new opportunities for their technology. They plan to share updates on collaborations, including one with Stanford Medicine. SOHM aims for higher revenue growth in 2024, partly driven by the new ABBIE kits.
SOHM, Inc. (OTC PINK:SHMN), un'azienda nel settore farmaceutico e biotecnologico, ha annunciato di aver ricevuto ordini pre-lancio per i loro kit di tecnologia ABBIE. Questo rappresenta un traguardo significativo mentre l'azienda si sposta dalla ricerca e sviluppo alla commercializzazione dei kit di tecnologia GLP ABBIE. Si prevede che il mercato dei kit CRISPR/Cas9 raggiunga 17,4 miliardi di dollari entro il 2032.
La tecnologia ABBIE di SOHM offre un integrazione più rapida ed efficiente delle sequenze genetiche nel DNA cellulare rispetto ai metodi tradizionali, riducendo tempi e costi. I dati dell'azienda mostrano che l'mRNA che esprime ABBIE con guide RNA integra il DNA donatore in modo più efficiente rispetto a senza guide RNA.
La direzione è fiduciosa che questi ordini pre-lancio apriranno nuove opportunità per la loro tecnologia. Hanno in programma di condividere aggiornamenti sulle collaborazioni, tra cui una con Stanford Medicine. SOHM punta a una maggiore crescita dei ricavi nel 2024, parzialmente guidata dai nuovi kit ABBIE.
SOHM, Inc. (OTC PINK:SHMN), una empresa de farmacéutica y biotecnología, ha anunciado que ha recibido pedidos previos al lanzamiento de sus kits de tecnología ABBIE. Esto marca un hito significativo a medida que la empresa pasa de la I+D a la comercialización de los Kits de Tecnología GLP ABBIE. Se proyecta que el mercado de kits CRISPR/Cas9 alcanzará 17,4 mil millones de dólares para 2032.
La tecnología ABBIE de SOHM ofrece una integración más rápida y eficiente de las secuencias genéticas en el ADN celular en comparación con los métodos tradicionales, reduciendo el tiempo y los costos. Los datos de la empresa muestran que el mRNA que expresa ABBIE con ARN guía integra el ADN donante de manera más eficiente que sin ARN guía.
La dirección confía en que estos pedidos previos al lanzamiento abrirán nuevas oportunidades para su tecnología. Tienen previsto compartir actualizaciones sobre colaboraciones, incluida una con Stanford Medicine. SOHM aspira a un mayor crecimiento de ingresos en 2024, impulsado en parte por los nuevos kits ABBIE.
SOHM, Inc. (OTC PINK:SHMN), 제약 및 생명공학 회사는 ABBIE 기술 키트의 사전 발주를 받았다고 발표했습니다. 이는 GLP ABBIE 기술 키트의 상업화를 위해 R&D에서 전환하는 중요한 이정표입니다. CRISPR/Cas9 키트 시장은 2032년까지 174억 달러에 이를 것으로 예상됩니다.
SOHM의 ABBIE 기술은 전통적인 방법에 비해 유전자 서열을 세포 DNA에 더 빠르고 효율적으로 통합할 수 있으며, 시간과 비용을 절감합니다. 회사의 데이터에 따르면, 가이드 RNA가 있는 ABBIE 발현 mRNA가 가이드 RNA 없이 기증자 DNA를 더 효율적으로 통합합니다.
경영진은 이러한 사전 발주가 기술에 대한 새로운 기회를 열 것이라 확신하고 있습니다. 그들은 Stanford Medicine과의 협력을 포함하여 업데이트를 공유할 계획입니다. SOHM은 2024년 더 높은 수익 성장을 목표로 하고 있으며, 이는 새로운 ABBIE 키트에 의해 일부 주도될 것입니다.
SOHM, Inc. (OTC PINK:SHMN), une entreprise pharmaceutique et biotechnologique, a annoncé avoir reçu des commandes en pré-lancement pour ses kits de technologie ABBIE. Cela marque une étape importante alors que l'entreprise passe de la recherche et développement à la commercialisation des kits de technologie GLP ABBIE. On prévoit que le marché des kits CRISPR/Cas9 atteindra 17,4 milliards de dollars d'ici 2032.
La technologie ABBIE de SOHM offre une intégration plus rapide et plus efficace des séquences génétiques dans l'ADN cellulaire par rapport aux méthodes traditionnelles, réduisant ainsi le temps et les coûts. Les données de l'entreprise montrent que l'ARNm exprimant ABBIE avec des ARN guides intègre l'ADN donneur de manière plus efficace qu'en l'absence d'ARN guides.
La direction est confiante que ces commandes en pré-lancement ouvriront de nouvelles opportunités pour leur technologie. Ils prévoient de partager des mises à jour sur les collaborations, y compris une avec Stanford Medicine. SOHM vise à une croissance des revenus plus élevée en 2024, en partie alimentée par les nouveaux kits ABBIE.
SOHM, Inc. (OTC PINK:SHMN), ein Unternehmen der Pharma- und Biotechnologiebranche, hat bekannt gegeben, dass es Vorbestellungen für ihre ABBIE-Technologiekits erhalten hat. Dies stellt einen bedeutenden Meilenstein dar, da das Unternehmen von Forschung und Entwicklung zur Kommerzialisierung der GLP ABBIE-Technologiekits übergeht. Der Markt für CRISPR/Cas9-Kits wird voraussichtlich bis 2032 17,4 Milliarden Dollar erreichen.
Die ABBIE-Technologie von SOHM bietet eine schnellere und effizientere Integration genetischer Sequenzen in die Zell-DNA im Vergleich zu traditionellen Methoden, was Zeit und Kosten spart. Die Daten des Unternehmens zeigen, dass ABBIE-expressierendes mRNA mit Leit-RNAs das Spender-DNA effizienter integriert als ohne Leit-RNAs.
Die Geschäftsleitung ist zuversichtlich, dass diese Vorbestellungen neue Möglichkeiten für ihre Technologie eröffnen werden. Sie planen, Updates zu Kooperationen zu teilen, einschließlich einer mit Stanford Medicine. SOHM strebt ein höheres Umsatzwachstum im Jahr 2024 an, teilweise bedingt durch die neuen ABBIE-Kits.
- Received pre-launch orders for ABBIE Technology kits
- Transitioning from R&D to commercialization of GLP ABBIE Technology Kits
- CRISPR/Cas9 kits market expected to reach $17.4 billion by 2032
- ABBIE technology offers faster and more efficient genetic integration at reduced costs
- Collaboration with Stanford Medicine in progress
- Management expects higher revenue growth in 2024 partly due to ABBIE kits
- None.
CHINO HILLS, CA / ACCESSWIRE / September 25, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has received ABBIE Technology kits pre-launch orders.
Dr. David Aguilar, COO, shared that the company has received pre-launch and pre-orders for our ABBIE technology kits. This is significant miles stone for the company and we are very happy to transition from Research and Development to commercialization of GLP ABBIE Technology Kits.
The current CRISPR/Cas9 kits business is expected to grow
This milestone has given us a boost to all our scientist and confidence in our technology and thereby making difference in the pharmaceutical / biotech space.
Our data shows that ABBIE expressing mRNA (ABBIE mRNA) with guide RNAs directed to AAVS1 integrates a donor DNA with green fluorescent protein (GFP) and antibiotic resistance into cells much more efficiently than ABBIE mRNA provided with donor DNA, but no guide RNAs.
Our kits are for faster and efficient integration of a chosen genetic sequence into the DNA of a cell including cells of an organism. Our kits significantly reduce the timing of integrating a DNA sequence at a very reduced cost compared to virus or genetic recombination using CRISPR/Cas9. The reduced time also lessens the impact of prolonged experimentation on the environment due to decreased use of materials.
This success encourages all of us and we are so hopeful for our all-pipeline products for our technology and in coming time, we shall share more updates on it including the collaboration with Stanford Medicines.
We are confident that these pre-launch and further orders will continue to bring us new dimensions, new opportunities and new avenues for our technology in the coming days.
Management remains committed to ensuring that SOHM achieves higher revenue growth in 2024 compared to previous years. This includes the revenues from our new ABBIE kits. Dr. David Aguilar, COO added.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
FAQ
What is the significance of SOHM Inc. (SHMN) receiving pre-launch orders for ABBIE Technology kits?
How does SOHM's ABBIE technology compare to traditional CRISPR/Cas9 methods?
What is the projected market size for CRISPR/Cas9 kits by 2032?
Is SOHM Inc. (SHMN) collaborating with any notable institutions on its ABBIE technology?
